| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.036 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | 0.12 | 0.6 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |